drugset / Trial / NCT06513286
TherVacB - A Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine Candidate
Phase 1/2
Recruiting
81 enrolled
Michael Hoelscher
Institute of Virology Helmholtz Zentrum München Trogerstraße 30 81675 Munich, Germany · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This study is an open-label, ascending dose phase 1b/2a trial to assess the safety and immunogenicity of a heterologous protein prime/MVA boost therapeutic hepatitis B vaccine in patients with chronic HBV who are virally suppressed with oral anti-viral therapies.
Timeline
- Start
- 2025-06-12
- Primary completion
- 2026-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HBcoreAg | Unknown | — | Intramuscular |
| Subject | HEPLISAV-B | Vaccine | — | Intramuscular |
| Subject | MVA-HBVac | Unknown | — | Intramuscular |